Cuvitru market seen growing through 2030 on immunodeficiency demand

The Business Research Company says the global Cuvitru market is gaining momentum through 2030 as more patients are diagnosed with immunodeficiency disorders and demand rises for home-based immunoglobulin therapy. Asia-Pacific led the market in 2025, while higher healthcare spending and an aging population are adding to growth.

Why it matters: - The Cuvitru market is tied to treatment access for patients with primary immunodeficiency disorders. - Growth in the market reflects broader demand for immunoglobulin replacement therapies that can reduce infections and support immune defense. - Rising diagnosis rates, aging populations and higher health spending are expanding the patient pool and the treatment market.

What happened: - The Business Research Company released a 2030 market forecast for Cuvitru, an immunoglobulin-based medication used to treat primary immunodeficiencies. - The report says Asia-Pacific was the largest regional market in 2025. - The analysis also covers Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The report includes a free sample download and a full market report link: More information and the full report.

The details: - Cuvitru is designed to supplement antibodies that patients with primary immunodeficiencies cannot produce on their own. - The therapy is used in conditions such as chronic granulomatous disease and severe combined immunodeficiency. - The report says historical growth has been supported by better detection of primary immunodeficiency disorders, wider plasma collection networks, improved immunoglobulin purification and broader use of replacement therapies. - Future growth is expected to come from home healthcare immunotherapy, self-administration demand, investment in plasma fractionation capacity, personalized dosing and innovations in immunoglobulin formulation. - The report highlights a growing preference for subcutaneous immunoglobulin treatments, home-based infusion therapies, longer-term management of immunodeficiency conditions, patient-centered delivery innovations and improved safety of plasma-derived products. - In 2023, the Immune Deficiency Foundation reported about 1,177 patients living with primary immunodeficiency in the US, with common variable immune deficiency accounting for 62% of diagnoses. - A November 2024 Health Foundation report said NHS England funding is projected to rise from £171 billion ($216.10 billion) in 2023/24 to £192 billion ($242.64 billion) by 2025/26. - Population Reference Bureau data from January 2024 says the number of Americans 65 and older is expected to increase from 58 million in 2022 to 82 million by 2050, a 47% rise. - The same projection says the share of the U.S. population age 65 and older will rise from 17% to 23% by 2050.

Between the lines: - The forecast points to a market shaped less by one drug alone and more by the shift toward easier, at-home treatment models. - The emphasis on subcutaneous delivery suggests manufacturers and providers are competing on convenience as much as on clinical need. - Asia-Pacific’s lead suggests growth is being pulled by patient volume and expanding healthcare infrastructure, not just mature-market demand.

What's next: - The Business Research Company says future market growth will depend on adoption of home healthcare immunotherapy and self-administration models. - Additional upside will likely come from more plasma processing capacity and better product formulation. - The report’s 2026 edition adds market attractiveness scoring, TAM analysis, company scoring matrix graphics, Excel-based forecasting dashboards, market hotspots infographics, and updated graphics and tables. - The company also points readers to its social channels, including LinkedIn and the company's social pages on LinkedIn, Facebook and X.

The bottom line: - Cuvitru’s outlook through 2030 is being driven by more diagnosis, more home treatment and a larger aging population that needs immune support.